|
Patent landscape, scope, and claims: |
Analysis of United States Patent 11,433,066: A Pharmaceutical Patent Landscape Review
United States Patent 11,433,066, granted on September 6, 2022, to Bristol-Myers Squibb Company, protects methods of treating a B-cell malignancy. The patent claims are directed to administering a combination therapy including an anti-PD-1 antibody and a Bruton’s tyrosine kinase (BTK) inhibitor. This analysis examines the scope and claims of the patent and evaluates its position within the broader pharmaceutical patent landscape, focusing on the competitive environment and potential patentability challenges.
What is the Core Innovation Protected by Patent 11,433,066?
Patent 11,433,066 claims methods of treating B-cell malignancies, specifically by co-administering an anti-PD-1 antibody and a BTK inhibitor. The patent describes that this combination therapy results in a synergistic or additive therapeutic effect compared to administering either agent alone. The B-cell malignancies targeted include, but are not limited to, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL).
The patent’s disclosure describes specific examples of anti-PD-1 antibodies, such as nivolumab, and BTK inhibitors, including ibrutinib, acalabrutinib, and zanubrutinib. It also details various dosages, administration routes, and treatment durations. The core inventive concept lies in the identified synergistic therapeutic benefit of combining these two classes of drugs for specific hematological cancers.
What Are the Key Claims in Patent 11,433,066?
The patent contains multiple independent and dependent claims. Key claims revolve around the method of treatment.
-
Claim 1: A method of treating a B-cell malignancy in a subject, comprising co-administering to the subject: (a) an anti-PD-1 antibody; and (b) a Bruton’s tyrosine kinase (BTK) inhibitor.
-
Dependent Claims (Examples):
- Claims specifying the type of B-cell malignancy, such as DLBCL, CLL, or MCL.
- Claims specifying the anti-PD-1 antibody, including nivolumab.
- Claims specifying the BTK inhibitor, including ibrutinib, acalabrutinib, or zanubrutinib.
- Claims specifying the formulation or dosage of the antibodies and inhibitors.
- Claims specifying the order of administration or simultaneous administration.
The claims are method-of-treatment claims, which are often subject to specific patentability requirements and enforcement challenges, particularly concerning novelty, obviousness, and enablement.
How Does Patent 11,433,066 Define the Scope of Protection?
The scope of protection granted by Patent 11,433,066 is defined by its broadest independent claims, particularly Claim 1. This claim protects any method of treating a B-cell malignancy that involves the co-administration of any anti-PD-1 antibody and any BTK inhibitor. The breadth is further amplified by the dependent claims, which narrow the scope to specific, commercially relevant examples of both drug classes and disease indications.
The patent’s enablement and written description requirements are crucial for defining the practical scope. If the patent fails to adequately describe how to make and use the claimed invention across the full scope of the claims, the effective scope may be narrower. This involves demonstrating sufficient evidence of the claimed synergistic effect for the broad categories of antibodies and inhibitors, as well as for the listed B-cell malignancies.
What is the Patent Landscape for Anti-PD-1 Antibodies and BTK Inhibitors?
The patent landscape for both anti-PD-1 antibodies and BTK inhibitors is highly competitive and complex, characterized by extensive patent filings and numerous granted patents covering various aspects of these drug classes.
Anti-PD-1 Antibodies
- Key Players: Bristol-Myers Squibb (Opdivo, nivolumab), Merck & Co. (Keytruda, pembrolizumab), AstraZeneca (Imfinzi, durvalumab), Roche (Tecentriq, atezolizumab).
- Patented Aspects:
- Composition of matter patents for the antibodies themselves (e.g., amino acid sequences, CDR regions).
- Manufacturing processes.
- Formulations.
- Methods of use for specific indications.
- Combination therapies.
- Patent Expirations: The earliest composition of matter patents for some anti-PD-1 antibodies are beginning to expire or have already expired, paving the way for biosimilar competition. However, patents covering newer formulations, manufacturing improvements, and specific new indications or combination therapies can extend market exclusivity.
Bruton’s Tyrosine Kinase (BTK) Inhibitors
- Key Players: AbbVie (Imbruvica, ibrutinib), Acerta Pharma/AstraZeneca (Calquence, acalabrutinib), BeiGene (Brukinsa, zanubrutinib), Eli Lilly (LOXO-305/pirtobrutinib - reversible inhibitor).
- Patented Aspects:
- Composition of matter patents for the small molecule inhibitors.
- Polymorphs and salt forms.
- Manufacturing processes.
- Methods of use for specific indications.
- Second-generation inhibitors designed for improved efficacy, safety, or reduced off-target effects.
- Patent Expirations: Ibrutinib, the first-in-class BTK inhibitor, has seen its core composition of matter patents expire in major markets. Newer BTK inhibitors also have distinct patent protection covering their unique chemical structures and therapeutic uses.
How Do Patent 11,433,066 Claims Intersect with Existing Patents?
Patent 11,433,066 is a method-of-treatment patent that leverages existing drug classes. Its intersection with the existing landscape is primarily through:
-
Combination Therapy Patents: This patent claims a specific combination therapy. Other entities may hold patents covering different combinations of anti-PD-1 antibodies and BTK inhibitors, or even other immunotherapies and BTK inhibitors. The novelty and non-obviousness of Patent 11,433,066 would have been assessed against prior art that disclosed or suggested such combinations.
-
Individual Drug Patents: The patent relies on the availability of anti-PD-1 antibodies and BTK inhibitors that are themselves protected by patents. For instance, if a specific anti-PD-1 antibody (e.g., nivolumab) is still under robust composition of matter patent protection, its use in the claimed method would be covered by the antibody patent as well. If the antibody patent has expired, then the method-of-treatment patent becomes critical for controlling the use of that specific antibody in combination with a BTK inhibitor.
-
Indication-Specific Patents: Patents may exist for the use of anti-PD-1 antibodies or BTK inhibitors as monotherapies for specific B-cell malignancies. Patent 11,433,066 claims a combination therapy, which, if novel and non-obvious over the prior art of monotherapy uses, would offer distinct protection.
What are the Potential Patentability Challenges for Patent 11,433,066?
The patentability of method-of-treatment claims, particularly those involving combination therapies, can face challenges. Key areas include:
- Novelty: Was the specific combination of an anti-PD-1 antibody and a BTK inhibitor for treating B-cell malignancies previously disclosed or known? Prior art may include scientific publications, earlier patent applications, or existing drug labels.
- Non-Obviousness (Obviousness-Type Double Patenting): Even if novel, would the combination have been obvious to a person skilled in the art at the time of invention? This is a significant consideration for combination therapies. Examiners assess whether prior art would have suggested combining known agents, especially if synergistic effects were predictable or if the agents were known to be effective in treating similar conditions. The patent’s disclosure of specific, unexpected synergistic effects is critical here.
- Enablement and Written Description: Does the patent adequately describe the invention across its full scope? For broad claims encompassing multiple antibodies, inhibitors, and malignancies, the patent must provide sufficient guidance and experimental data to demonstrate that one skilled in the art could practice the claimed methods without undue experimentation. This includes demonstrating the synergistic effect.
- Subject-Matter Eligibility (35 U.S.C. § 101): While less common for drug combination therapies in recent years compared to diagnostic methods, claims can still be challenged if they are deemed to be directed to natural phenomena or abstract ideas without a significant inventive concept.
What is the Competitive Impact of Patent 11,433,066?
The primary competitive impact of Patent 11,433,066 is the extension of market exclusivity for therapies combining anti-PD-1 antibodies with BTK inhibitors for B-cell malignancies.
- For Bristol-Myers Squibb: This patent provides a mechanism to defend its market share in the treatment of B-cell malignancies, particularly if it involves their own anti-PD-1 antibody (e.g., nivolumab) in combination with a BTK inhibitor. It can deter competitors from launching generic versions of the combination therapy or from developing similar combination products that infringe on the claimed methods.
- For Competitors: Competitors developing BTK inhibitors or new anti-PD-1 antibodies will need to navigate this patent. They may need to:
- Develop non-infringing combination therapies.
- Challenge the validity of Patent 11,433,066 through reexamination or litigation.
- Seek licenses from Bristol-Myers Squibb.
- Wait for the patent to expire.
The patent’s strength will depend on the robustness of its claims, the validity of its asserted inventive step, and the clarity of its enablement. The specific wording of the claims, particularly the definitions of "anti-PD-1 antibody" and "BTK inhibitor," will determine its breadth against evolving technologies and new drug entrants.
How Might This Patent Be Enforced or Challenged?
Enforcement of Patent 11,433,066 would typically involve litigation against entities that are manufacturing, marketing, or using the claimed combination therapy without a license. For example, a generic manufacturer seeking to market a BTK inhibitor for use in combination with a particular anti-PD-1 antibody could be accused of infringement.
Challenges to the patent can occur through:
- Inter Partes Review (IPR) at the USPTO: Competitors can file IPR petitions to challenge the patent’s validity based on prior art. This administrative procedure is often faster and less expensive than district court litigation.
- Declaratory Judgment Actions: A party facing a threat of infringement suit might preemptively file a lawsuit seeking a declaration of non-infringement or invalidity.
- District Court Litigation: Patent owners can sue infringers in federal district court. Defendants will typically counter with arguments of non-infringement and invalidity.
The commercial success of the combination therapy and the perceived threat it poses to competitors will drive the likelihood of both enforcement actions and validity challenges. The breadth of the claims, particularly regarding the types of antibodies and inhibitors covered, will be a focal point in any legal dispute.
Key Takeaways
- United States Patent 11,433,066 protects methods of treating B-cell malignancies using a combination of anti-PD-1 antibodies and BTK inhibitors.
- The patent’s claims are broad, covering generic classes of drugs and specific examples, and are critical for defending market exclusivity in this therapeutic area.
- The competitive landscape for both anti-PD-1 antibodies and BTK inhibitors is dense with patents, making the intersection of combination therapy patents with individual drug patents crucial.
- Potential challenges to Patent 11,433,066 may include novelty, non-obviousness, enablement, and written description issues, particularly given the nature of combination therapy claims.
- The patent's enforcement or challenge will be influenced by the commercial significance of the claimed combination therapies and the competitive pressure from other pharmaceutical companies.
Frequently Asked Questions
-
What specific B-cell malignancies are covered by Patent 11,433,066?
The patent covers a range of B-cell malignancies, explicitly mentioning diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL) as examples, with the potential to extend to others implied by the general claim language.
-
Does Patent 11,433,066 cover the individual drugs themselves (anti-PD-1 antibody or BTK inhibitor)?
No, Patent 11,433,066 is a method-of-treatment patent. It does not claim the composition of matter of the individual anti-PD-1 antibodies or BTK inhibitors, which are likely covered by separate patents. Its protection lies in the specific combination therapy regimen for treating B-cell malignancies.
-
How long is the patent protection for Patent 11,433,066 expected to last?
United States patents generally have a term of 20 years from the filing date, subject to maintenance fees. However, patent term adjustments (PTA) and extensions (PTE) can extend the effective term. The filing date for this patent would determine its standard expiration, and any applicable extensions would further define its duration of enforceability.
-
Can generic manufacturers market BTK inhibitors if Patent 11,433,066 is in force?
Generic manufacturers can market BTK inhibitors if their composition of matter patents have expired and they do not infringe any valid and enforceable claims of Patent 11,433,066. If Patent 11,433,066 claims methods of use that would be practiced by a generic product, then its marketing could be subject to infringement unless the patent is invalid or the manufacturer has a license.
-
What are the implications if an anti-PD-1 antibody used in the claimed method is off-patent?
If the anti-PD-1 antibody is no longer covered by its own composition of matter patent, Patent 11,433,066 becomes a more significant barrier to competition for the combination therapy. It would prevent others from promoting or marketing that specific antibody for use in combination with a BTK inhibitor for the claimed B-cell malignancies, even if the antibody itself is available as a biosimilar.
Citations
[1] Bristol-Myers Squibb Company. (2022). Method of treating B-cell malignancy (U.S. Patent No. 11,433,066). Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
